Iovance Biotherapeutics
IOVA
253 hedge funds and large institutions have $462M invested in Iovance Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 79 reducing their positions, and 40 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
67% more call options, than puts
Call options by funds: $7.47M | Put options by funds: $4.47M
22% more capital invested
Capital invested by funds: $379M → $462M (+$83M)
3% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 79
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
1% less funds holding
Funds holding: 255 → 253 (-2)
7.1% less ownership
Funds ownership: 65.97% → 58.87% (-7.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$9.89M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.07M |
| 3 |
BlackRock
New York
|
+$6.42M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.31M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11.6M |
| 2 |
Renaissance Technologies
New York
|
-$8.41M |
| 3 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$6.38M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.4M |
| 5 |
Two Sigma Investments
New York
|
-$4.47M |
IOVA Hedge Fund Activity: Q3 2025 in Review
253 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2025, worth a combined $462M — up 22% from $379M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IOVA positions and 40 closed out — a net gain of 1 holder — while 81 added to existing stakes and 79 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $9.89M. The largest seller was Millennium Management, cutting an estimated $11.6M.
- 253 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2025, down from 255 in Q2 2025.
- Funds reported $462M of Iovance Biotherapeutics stock for Q3 2025, up 22% quarter-over-quarter.
- 41 funds opened new Iovance Biotherapeutics positions in Q3 2025 and 40 closed out, a net change of +1 holder.
- The largest Iovance Biotherapeutics buyer in Q3 2025 was Palo Alto Investors, an estimated $9.89M added.
- The largest Iovance Biotherapeutics seller in Q3 2025 was Millennium Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2025.